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in this population over 5 years as a result of this intervention. Health care payors should
consider development of financial incentives to encourage collaborative quality improve-
ment programs.
1077-74 Marked Underutilization and Geographic Variation in 
Secondary Prevention Pharmacologic Therapy in 
Patients With Chronic Angina Undergoing Treatment 
With Enhanced External Counterpulsation
Andrew D. Michaels, Sheryl Kelsey, Ozlem Soran, Elizabeth E. Kennard, University of 
California, San Francisco, San Francisco, CA, University of Pittsburgh, Pittsburgh, PA
Introduction: Despite the importance of antiplatelet agents, beta-blockers, angiotensin-
converting enzyme inhibitors (ACEIs), and hypolipidemic agents in patients with chronic
coronary artery disease (CAD), several studies have suggested that these agents are
substantially underutilized. Hypothesis: We sought to describe the contemporary use of
these pharmacologic agents among patients with chronic angina who were referred for
treatment with enhanced external counterpulsation (EECP). EECP is reserved for
patients with angina despite maximal medical therapy and revascularization. We sought
to test the hypothesis that there is geographic variation in the use of these therapies in
CAD patients. Methods: The International EECP Patient Registry (IEPR) enrolls consec-
utive patients undergoing EECP for chronic angina. We analyzed data on 4388 US
patients who underwent EECP for angina and were enrolled in the IEPR beginning in
January 1998. US Census definitions were used to categorize patients into 4 geographic
regions: Northeast (NE), West, South, and Midwest (MW). Results: This study included
1350 NE patients, 463 West patients, 1232 South patients, and 1343 MW patients.
Demographic and clinical characteristics, including age, sex, Caucasian race, prior MI,
diabetes, and hyperlipidemia, were similar among the 4 regions. Patients in the South
had the lowest incidence of prior coronary revascularization, multivessel disease, and
quality of life, while having the highest incidence of current smoking (9.5% in South vs
7.6% non-South). Patients in the MW had the highest mean angina class. South patients
had the lowest use of cardiac medication, including beta-blockers (55% in South vs 70%
non-South; p<.001) and aspirin (65% vs 74%; p<.001). There was no geographic varia-
tion in the use of calcium blockers (45% overall), ACEIs (38%), or lipid-lowering agents
(70%). Conclusions: There is substantial underutilization of antiplatelet agents, beta-
blockers, ACEIs, and hypolipidemic agents in US patients with chronic stable angina.
Variation across the country is striking, but all areas can improve the care of such
patients by increasing the appropriate use of these agents.
1077-75 Coronary Artery Bypass Grafting: Are We Getting With 
the Program?
Morley A. Herbert, Syma L. Prince, Mitchell J. Magee, Eric Eichhorn, Cardiopulmonary 
Research Science and Technology Institute, Dallas, TX, Medical City Dallas Hospital, 
Dallas, TX
Background: To minimize future cardiac events, American Heart Association guidelines
(1995, 2001) for treatment of patients with coronary artery disease recommended that
patients should be discharged on appropriate medications- beta-blocker, ACE inhibitor,
aspirin or other anti-platelet medication and cholesterol lowering medication when appro-
priate. This study examines discharge medicines prescribed patients after coronary
artery bypass grafting (CABG).
Methods: Data was exported from our STS certified database on 6914 patients undergo-
ing CABG between Jan 2000 and July 2003, and analyzed for the use of beta-blockers,
ACE inhibitors, aspirin (or other anti-platelet drug) and cholesterol lowering agent at dis-
charge.
Results: At discharge 10.3% of patients were prescribed all four classes of drugs, a fur-
ther 34.2% received 3 of the drugs, and 4.3% had no drugs prescribed (Table 1)
Of patients receiving only 1 drug at discharge, 86% were given aspirin or other antiplate-
let medication. When prescribed 2 drugs, 96.0% received aspirin, while beta-blockers
were prescribed to 56.9% and cholesterol lowering agents to 32.3% of the patients. In 3
drug regimens, aspirin was used in 99.1%, cholesterol lowering agents in 87.1% and
beta-blockers in 84.4% of the patients. Only 29.4% received a prescription for an ACE-
inhibitor.
Conclusions: Despite published medication guidelines, only 44.5% of patients being dis-
charged after CABG received prescriptions following the recommended drug regimen.
1077-76 Holiday Heart: Decreased Use of Evidence-Based 
Therapies in Patients With Acute Myocardial Infarction 
Admitted During Holiday Weeks
Trip J. Meine, Manesh R. Patel, Venita DePuy, Lesley Curtis, Sunil V. Rao, Kevin J. 
Schulman, James G. Jollis, Duke University Medical Center, Durham, NC, Duke Clinical 
Research Institute, Durham, NC
Background: Previous studies have found an increased mortality from myocardial infarc-
tion in December. We investigated the relationship between the use of evidence-based
therapies and admission during holiday weeks.
Methods: 134,609 patients in an observational Medicare database admitted with myo-
cardial infarction from 1994-1996 were studied. Patients admitted during the last 2 weeks
of December and the first week of January were compared with patients admitted all
other weeks. A model adjusting for patient, physician, hospital, and geographic charac-
teristics was used to determine a relationship between week of admission and the use of
proven therapies.
Results: Patients admitted during the holidays were less likely to receive aspirin, beta
blockers or reperfusion therapy, specifically primary coronary intervention (PCI) (Table 1).
Mortality in patients admitted during the holidays was also significantly higher at 30 days
and 1 year. After adjustment, patients admitted during the holidays remained less likely to
receive PCI (RR 0.9, p <0.01).
Conclusion: Patients admitted during holiday weeks are less likely to receive evidence-
based therapies, specifically primary coronary intervention.
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1096-67 Balloon Mitral Valvuloplasty Performed in Mobile 
Catheterization Laboratory as Part of Community 
Outreach Program at Primary Care Hospitals
Praveen Chandra, Ravi Kasliwal, S. N. Misra, B. Rawat, R. B. Panwar, Ajay Kanojia, 
Naresh Trehan, Ashok Seth, Escorts Heart Institute and Research Centre, New Delhi, 
India, Norvic, Nepal
Several patients of pure severe mitral stenosis suffer due to lack of definitive treatment
options like balloon mitral valvuloplasty (BMV) in developing countries, due to prevailing
socioeconomic conditions. We present a new strategy of taking tertiary level care to peo-
ple’s doorsteps by performing BMV in Mobile Cardiac Catheterization Laboratory near a
peripheral primary care hospital as part of a Community Outreach Program. Method:
This multicentric study performed at 6 centres in India and Nepal was divided into 2
phases. Phase I included 150 patients and all procedures were done with a surgical
standby. After the success of Phase I, 210 patients were treated in phase II, without sur-
gical standby. Patients were assessed for suitability for BMV by transthoracic echocardio-
gram (TTE) & transesophageal echocardiogram (TEE) in phase I and only TTE in phase
II. Exclusion criteria were moderate to severe mitral regurgitation (MR), presence of left
atrial or appendage clots and a Wilkins’ echocardiographic score of > 8. Procedure was
done using Inoue Balloon technique with TTE guidance. Results are summarized in the
table 1. Age range was 8-80 yrs and 53% were females . Conclusion: BMV is feasible
and safe even if done in a mobile catheterization laboratory in a primary care hospital
setting and can be undertaken without any surgical standby. These results are of
immense significance especially in developing countries where lack of facilities preclude
treatment of many deserving patients of severe mitral stenosis.
% with 4 drugs % with 3 drugs
2000 5.9 29.3
2001 10.9 34.1
2002 15.0 37.7
2003 11.4 42.4
Females/Males 9.0/10.8 31.9/35.0
Caucasian 9.6 34.2
African-American 18.6 31.8
Hispanic 15.1 32.0
Other 17.3 38.9
On Pump/Off Pump 10.2/10.6 32.7/36.3
Table 1: Use of Evidence-Based Therapies and Outcomes in Patients with Acute 
Myocardial Infarction
Holiday
Weeks
Rest of Year p 
Aspirin Use (during admission) 77.2% 78.2% 0.02
Aspirin Use (at discharge) 69.0% 69.5% 0.4
Beta Blocker Use (during admission) 43.3% 44.8% 0.002
Beta Blocker Use (at discharge) 28.7% 30.6% <0.0001
Reperfusion Therapy 16.3% 17.4% 0.004
Primary Coronary Intervention 12.5% 15.3% <0.0001
30-Day Mortality 22.5% 20.5% <0.0001
1-Year Mortality 37.2% 34.9% <0.0001
